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Abstract
Burkholderia pseudomallei is the causative agent of the severe tropical disease melioidosis,
which commonly presents as sepsis. The B. pseudomallei K96243 genome encodes eleven
predicted autotransporters, a diverse family of secreted and outer membrane proteins often
associated with virulence. In a systematic study of these autotransporters, we constructed
insertion mutants in each gene predicted to encode an autotransporter and assessed them
for three pathogenesis-associated phenotypes: virulence in the BALB/c intra-peritoneal
mouse melioidosis model, net intracellular replication in J774.2 murine macrophage-like
cells and survival in 45% (v/v) normal human serum. From the complete repertoire of eleven
autotransporter mutants, we identified eight mutants which exhibited an increase in median
lethal dose of 1 to 2-log10 compared to the isogenic parent strain (bcaA, boaA, boaB, bpaA,
bpaC, bpaE, bpaF and bimA). Four mutants, all demonstrating attenuation for virulence, ex-
hibited reduced net intracellular replication in J774.2 macrophage-like cells (bimA, boaB,
bpaC and bpaE). A single mutant (bpaC) was identified that exhibited significantly reduced
serum survival compared to wild-type. The bpaCmutant, which demonstrated attenuation
for virulence and net intracellular replication, was sensitive to complement-mediated killing
via the classical and/or lectin pathway. Serum resistance was rescued by in trans comple-
mentation. Subsequently, we expressed recombinant proteins of the passenger domain of
four predicted autotransporters representing each of the phenotypic groups identified: those
attenuated for virulence (BcaA), those attenuated for virulence and net intracellular
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replication (BpaE), the BpaC mutant with defects in virulence, net intracellular replication
and serum resistance and those displaying wild-type phenotypes (BatA). Only BcaA and
BpaE elicited a strong IFN-γ response in a restimulation assay using whole blood from sero-
positive donors and were recognised by seropositive human sera from the endemic area.
To conclude, several predicted autotransporters contribute to B. pseudomallei virulence
and BpaC may do so by conferring resistance against complement-mediated killing.
Introduction
Burkholderia pseudomallei is a motile Gram-negative bacillus which is a saprophyte of tropical
and sub-tropical soils and water. It is the causative agent of melioidosis, a febrile illness with
acute and chronic disease states, which often presents with sepsis. Melioidosis is associated
with high mortality rates in endemic regions. For example, in North-Eastern Thailand it is the
third most common cause of death from infectious disease and has a mortality rate of approxi-
mately 44% [1]. Cases of melioidosis have been reported outside of the traditional endemic re-
gions of Thailand, Singapore, Malaysia and northern Australia, with other Asia-Pacific
countries, the Caribbean, Central and South America as well as West and East Africa emerging
on the map of worldwide disease distribution and prevalence [2]. Understanding of the molec-
ular mechanisms of the pathogenesis of melioidosis has expanded considerably in recent years,
primed in part by the availability of complete genome sequences. B. pseudomallei has a genome
of>7 Mb comprising two chromosomes that encode many virulence factors, including cap-
sule, lipopolysaccharide (LPS), flagella, quorum sensing systems and numerous protein secre-
tion systems, including Type III and Type VI pathways [reviewed in [3,4]].
For bacterial pathogens that enter the blood, the magnitude of resistance of isolates to killing
in serum associates with the severity of septicaemic disease [5]. The complement system, a
component of the innate immune response, is a cascade of proteins which results in deposition
of C3 on the microbial cell wall with the subsequent assembly of the C5b-C9 membrane attack
complex that mediates cell lysis [6]. Complement can be activated via three independent path-
ways, the classical, lectin or alternative arms, which recognise microbes via immune complexes,
polysaccharides, or foreign surfaces [7]. B. pseudomallei is resistant to the complement-mediat-
ed killing activity of normal human sera (NHS), being able to multiply in low levels of NHS
(10–30% (v/v)) and exhibiting resistance to killing in up to 90% (v/v) NHS [8]. The comple-
ment cascade is activated by B. pseudomallei within five minutes, with deposition of C3 and the
C5b-C9 membrane attack complex in a non-lytic manner [6]. Initial experiments demonstrat-
ed that B. pseudomallei predominately activated the alternative pathway of the complement
system [6]. However, reduced C3 deposition was subsequently noted when the classical and
lectin pathways were inactivated by EGTA/Mg2+ [9]. These data suggest that under varied con-
ditions (i.e. Ca2+ levels), different arms of the complement pathways are activated by B. pseudo-
mallei. Resistance to the alternative pathway has been attributed to the action of LPS O-antigen
as seen in other Gram-negative organisms [8,10]. Yet while an LPS (wbiI) mutant is killed by
the alternative arm of complement, lower levels of C3 deposition are observed compared to
wild-type [9]. A double LPS and capsule (wbiI and wcbB) mutant was found to display a greater
sensitivity to NHS than the LPS mutant alone (which itself displays an atypical capsule) and
this phenotype could be abrogated by addition of purified capsular polysaccharide but not LPS
[11]. But the acapsular mutant, which has normal LPS, demonstrated wild-type resistance to
NHS [10,12] despite an increased deposition of C3 [9,11]. These data suggest that the capsule
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acts as a physical barrier for C3 deposition in a non-bactericidal manner, but when this barrier
is absent other factors, i.e. LPS, are still able to provide resistance.
Autotransporters (ATs) comprise a large and diverse family of bacterial secreted and outer
membrane proteins, which are present in many Gram-negative bacterial pathogens and play
roles in numerous environmental and virulence-associated interactions including persistence,
adhesion, serum resistance and biofilm formation. ATs utilise the Type V secretion mecha-
nism, one of seven recognised secretion pathways in Gram-negative bacteria. A typical AT will
have a 20–400 kDa passenger domain that contains the effector functions and a 10–30 kDa β
barrel domain facilitating translocation across the outer membrane [13]. ATs can be further di-
vided into classical ATs and trimeric autotransported adhesins (TAAs). TAAs are so named
because each protein trimerises to form a single 12-stranded β barrel from their three 4-strand-
ed β barrel domains. In many instances, the passenger domain of a typical AT functions as an
adhesin [13,14]. The B. pseudomallei K96243 genome comprises genes encoding eleven pre-
dicted ATs, based on sequence similarity to known ATs [15,16], of which two are putative clas-
sical ATs and nine are predicted to be TAAs (reviewed in [16]; Table 1).
To date, the best studied of the B. pseudomallei ATs is BimA, a predicted TAA required for
intracellular motility. BimA is located at the bacterial pole where it recruits and polymerises
cellular actin to form actin tails which propel bacteria within, and between, host cells [22,23]. A
second AT, BbfA, plays a role in biofilm formation; a bbfAmutant was found to be affected in
its ability to form biofilms, as well as demonstrating attenuation for virulence via the intra-peri-
toneal route in the BALB/c murine melioidosis model [21]. However, a B. pseudomallei 1026b
mutant in the gene encoding this same TAA, independently named bpaF, was found to display
wild-type virulence via the intra-nasal route [15]. This result was part of a study of eight pre-
dicted TAAs (excluding BimA) which found that only BapC played a role in virulence via the
intra-nasal route in the BALB/c mouse model. This study also demonstrated that mutants in
bpaA, bpaB, bpaC, bpaD, bpaE, bpaF, boaA and boaB had reduced adhesion and/or invasion of
Table 1. Autotransporters ofB. pseudomallei and their published functions.
K96243
gene
Nomenclature Function Intracellular survival & replication Virulence Immunogenicity
Classical autotransporters
BPSL2237 BatA
BPSS0962 BcaA # invasion & plaques (A549) [17]
Trimeric autotransporter adhesions
BPSL1631 BpaC # adhesion & invasion (A549) [15]; #
adhesion (NHBE) [18]
# liver survival (i.n. route) [15]; wt
virulence (aerosol route) [18]
BPSL1705 BoaB # adhesion (A549) [15,19]
BPSL2063 BpaB # adhesion & invasion (A549) [15] ✓ [16]
BPSS0088 BpaD # adhesion & invasion (A549) [15] ✓ [20]
BPSS0796 BoaA # adhesion & invasion (A549) [15,19] ✓ [16]
BPSS0908 BpaE # adhesion, invasion & plaques (A549)
[15]
✓ [16,20]
BPSS1434 BpaA # adhesion & invasion (A549) [15] ✓ [20]
BPSS1439 BpaF, BbfA ‡;
^
Bioﬁlm
formation [21]
# invasion (A549) [15] ✓ [16]
BPSS1492 BimA^ Actin tails [22] # actin tails (J774), plaques (A549) [23] ✓ [16,20]
‡ nomenclature used in this manuscript
^ name based on phenotypic characterisation
doi:10.1371/journal.pone.0121271.t001
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A549 epithelial-like cell lines. Additionally, the bpaEmutant also showed reduced plaque for-
mation in A549 cell monolayers [15]. Plaque formation in A549 cell monolayers is also im-
paired by mutation of bimA, though whether this reflects a lack of actin-based membrane
protrusions or a defect in net intracellular replication is ill-defined [23]. The role of BoaA and
BoaB in epithelial adhesion had been earlier demonstrated by the expression of recombinant
BoaA and BoaB in a heterologous E. coli host resulting in an increased adhesive phenotype in
the E. coli cells [19]. The role of BpaC in epithelial adhesion was confirmed by expression of re-
combinant BpaC in E. coli. The protein was observed to be localized on the bacterial surface by
immunofluorescence microscopy [18]. A bpaCmutant of B. pseudomallei strain DD503 was
found to exhibit reduced adhesion to normal human bronchial epithelium (NHBE) relative to
its parent strain yet the bpaCmutant displayed no significant difference in virulence compared
to the parent strain in the BALB/c mouse intra-tracheal aerosol model. BpaC-specific antibod-
ies were detected in animals infected with the parent DD503 strain indicative of in vivo expres-
sion of BpaC [18]. Furthermore, screens using melioidosis patient sera found seven of the nine
TAAs to be immunogenic, and can therefore be inferred to be expressed in vivo [16,20]. Only
one study has focused on the classical ATs; a mutant lacking the putative protease BcaA was
found to have a reduced invasion and plaque formation in A549 cell lines but no virulence phe-
notype [17].
As part of a systematic study on the ATs of B. pseudomallei, we have constructed insertion
mutants in the genes encoding each of the eleven ATs of strain 10276. This includes the un-
named classical AT BPSL2237, which we have named BatA (Burkholderia autotransporter A).
Our study extends upon the work of Campos et al., 2013 [15,17] and Lafontaine et al., 2014
[18] by investigating the complete AT repertoire for different in vivo and in vitro assays of viru-
lence-associated phenotypes to elucidate the role of ATs in pathogenesis. Our data indicate
that most of the putative ATs play a role in the virulence of B. pseudomallei 10276 in BALB/c
mice when infection is delivered by the intra-peritoneal route (BcaA, BoaA, BoaB, BpaA,
BpaC, BpaE, BbfA and BimA). Four mutants, all demonstrating attenuation for virulence, also
exhibited reduced net intracellular replication in J774.2 macrophage-like cells (bimA, boaB,
bpaC and bpaE). Additionally, we have identified that one predicted TAA, BpaC, plays a role
in resistance to complement-mediated killing by 45% (v/v) NHS via the classical and/or lectin
arm of the complement pathway.
Materials and Methods
Bacterial strains, plasmids, media and growth conditions
All bacterial strains and plasmids reported in these studies are listed in Table 2. The strains
were routinely grown in Luria-Bertani (LB) broth with shaking or on LB with 1.5% (w/v) agar
at 37°C. Cultures were supplemented with antibiotics and/or 10mM isopropyl-β-D-thiogalac-
topyranoside (IPTG) as required; kanamycin was used at a final concentration of 500 μg/ml,
chloramphenicol at 100 μg/ml and tetracycline at 25 μg/ml.
Recombinant DNA techniques
Plasmid DNA isolation, PCR fragment purification and gel extraction were performed using
Bioline kits (London, UK) as per manufacturer’s instructions. Genomic DNA was isolated
from B. pseudomallei as previously described [29]. Restriction endonucleases and DNAmodi-
fying enzymes (New England Biolabs, Hitchin, UK) were used as per manufacturer’s instruc-
tions. PCR amplifications were performed using Advantage Taq (Clontech, Saint-Germain-en-
Laye, France) or Taq DNA polymerase (New England Biolabs, Hitchin, UK) in accordance
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Table 2. Strains and plasmids used in this study.
Strain, plasmid or cell line Characteristics Insertion point /
gene length a
Reference or source
B. pseudomallei:
NCTC 10276 Clinical isolate (wild-type) Dr T. Pitt (Public Health
Laboratory Service, London,
UK)
10276 (pME6032) 10276 harbouring the pME6032 plasmid This study
10276 (pME6032-bbfA) 10276 harbouring the pME6032 plasmid containing a full-length
copy of bbfA
[21]
10276 bpaC::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in bpaC 638bp/ 3372bp This study
10276 bpaC::pDM4 mutant
(pME6032)
10276 harbouring a pDM4 single cross-over insertion in bpaC
and the pME6032 plasmid
This study
10276 bpaC::pDM4 mutant
(pME6032-bpaC)
10276 harbouring a pDM4 single cross-over insertion in bpaC
and the pME6032 plasmid containing a full-length copy of bpaC
This study
10276 bpaC::pDM4 mutant
(pME6032-bbfA)
10276 harbouring a pDM4 single cross-over insertion in bpaC
and the pME6032 plasmid containing a full-length copy of bbfA
This study
10276 bpaB::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in bpaB 715bp/ 3270bp This study
10276 batA::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in batA 426bp/1830bp This study
10276 bpaD::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in bpaD 1470bp/2023bp This study
10276 boaA::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in boaA 459bp/4959bp This study
10276 bpaE::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in bpaE 557bp/2313bp This study
10276 bcaA::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in bcaA 526bp/3393bp This study
10276 bimA::pDM4 mutant 10276 harbouring a pDM4 single cross-over insertion in bimA 336bp/516bp [22]
10276 boaB::pKNOCK-Kan
mutant
10276 harbouring a pKNOCK-Kan single cross-over insertion in
boaB
476bp/1606bp This study
10276 bpaA::pKNOCK-Kan
mutant
10276 harbouring a pKNOCK-Kan single cross-over insertion in
bpaA
735bp/7902bp This study
10276 bbfA::pKNOCK-Kan
mutant
10276 harbouring a pKNOCK-Kan single cross-over insertion in
bbfA
692bp/4590bp [21]
E. coli:
S17-1 λpir Conjugal donor for pDM4-based plasmids (λpir hsdR pro thi;
chromosomal integrated RP4-2 Tc::Mu Km::Tn7).
[24]
BL21 (DE3) Protein expression strain (F—ompT gal dcm lon hsdSB(rB
- mB
-) λ
(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5])
[25]
Plasmids:
pDM4 7.1kb, CmR, λpir-dependent vector (oriR6K) with RP4 oriT [26]
pDM4-bpaC pDM4 containing a 509 bp XhoI- BglII internal fragment of bpaC This study
pDM4-bpaB pDM4 containing a 577 bp BamHI- XbaI internal fragment of bpaB This study
pDM4-batA pDM4 containing a 357 bp BamHI- XbaI internal fragment of batA This study
pDM4-bpaD pDM4 containing a 321 bp XbaI- EcoRI internal fragment of bpaD This study
pDM4-boaA pDM4 containing a 346 bp XhoI- BglII internal fragment of boaA This study
pDM4-bpaE pDM4 containing a 407 bp XhoI- BglII internal fragment of bpaE This study
pDM4-bcaA pDM4 containing a 364 bp XhoI- BglII internal fragment of bcaA This study
pKNOCK-Kan 2.2 kb, KanR, λpir-dependent vector (oriR6K) with RP4 oriT [27]
pKNOCK-Kan-boaB pKNOCK-Kan containing a 407 bp BamHI- XbaI internal fragment
of boaB
This study
pKNOCK-Kan-bpaA pKNOCK-Kan containing a 660 bp BamHI- XbaI internal fragment
of bpaA
This study
pME6032 9.8 kb, TetR, pVS1 derived shuttle vector with IPTG inducible
ptac promoter
[28]
pME6032-bpaC pME6032 containing a full-length copy of bpaC (3755bp) This study
(Continued)
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with manufacturer’s instructions. DNA sequencing was carried out at the Protein and Nucleic
Acid Laboratory, University of Leicester.
The single cross-over insertion mutants were generated using either pDM4 [26] or
pKNOCK-Kan [27] as described previously and in Table 2. Briefly, an internal fragment of the
gene encoding the AT was amplified by PCR from B. pseudomallei 10276 using primers with
engineered restriction enzyme sites (S1 Table). The PCR products containing the internal frag-
ment were digested with the relevant enzymes, alongside the vector, and these were ligated to-
gether. The recombinant plasmids were introduced into B. pseudomallei 10276 via conjugation
from E. coli S17-1 λpir [27] and inactivation of the gene encoding the AT was confirmed by
PCR and sequencing of the insertion boundaries.
To allow for in trans complementation of the bpaCmutant, the full-length bpaC gene was
amplified by PCR from B. pseudomallei 10276 using primers with engineered restriction en-
zyme sites (S1 Table). The PCR product containing the bpaC gene was digested with EcoRI and
XhoI and ligated into similarly digested pME6032 [28] under the control of a lac promoter to
form pME6032-bpaC (pME-bpaC).
For protein expression, a gene fragment encoding the passenger domain (without N-termi-
nal signal peptide or C-terminal membrane domain) was amplified by PCR from B. pseudomal-
lei 10276 using primers with engineered restriction enzyme sites (S1 Table). The protein
expression vector, pGEX4T1 (GE Healthcare, Little Chalfont, UK), was selected to construct
N-terminal recombinant glutathione-S-transferase (GST)-fusion proteins under the induction
of IPTG. The PCR products containing the passenger domain were digested with the relevant
enzymes, alongside the vector, and these were ligated together (Table 2). The recombinant
plasmids were transformed into E. coli BL21 (DE3) [25]. Recombinant fusion protein expres-
sion vectors were sequenced to confirm PCR accuracy.
All the genetic modifications detailed in this manuscript were performed with the consent
of the UK Health and Safety Executive and University of Leicester and Institute for Animal
Health Biological & GM Safety Committees. The work was done in full compliance with all rel-
evant risk assessments and the requirements of the Advisory Committee of Dangerous Patho-
gens for work with hazard group 3 micro-organisms and Home Office requirements for the
storage and use of Schedule 5 biothreat agents.
Table 2. (Continued)
Strain, plasmid or cell line Characteristics Insertion point /
gene length a
Reference or source
pGEX4T1 5.0 kb, AmpR, N-terminal GST fusion protein vector with IPTG
inducible ptac promoter and thrombin protease cleavage site
GE Healthcare
pGEX4T1-bpaE pGEX4T1 containing a 1575 bp passenger domain fragment of
bpaE
This study
pGEX4T1-bpaC pGEX4T1 containing a 2241 bp passenger domain fragment of
bpaC
This study
pGEX4T1-bcaA pGEX4T1 containing a 2145 bp passenger domain fragment of
bcaA
This study
pGEX4T1-batA pGEX4T1 containing a 933 bp passenger domain fragment of
batA
This study
a Gene length (bp) includes the region encoding the N-terminal passenger domain which would be cleaved upon protein transport across the
inner membrane.
doi:10.1371/journal.pone.0121271.t002
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Ethics Statement
All investigations involving animals were carried out under a UK Home Office Project Licence,
according to the requirements of the Animal (Scientific Procedures) Act 1986. Ethical approval
was granted by our local (Defence Science and Technology Laboratory, University of Leicester)
ethical review process according to the requirements of the Animal (Scientific Procedures) Act
1986. Animals were monitored a minimum of twice daily, or more frequently once disease oc-
curred. Clinical signs characteristic of disease, such as ruffled coats, hunched posture, lethargy,
eye problems, neurological complications and reduced mobility were used to score disease se-
verity as mild, moderate or severe. Animals that reached severe disease (Defence Science and
Technology Laboratory) or a moderate lethargic state (University of Leicester) were culled via
cervical dislocation according to schedule 1 of the Animal (Scientific Procedures) Act 1986.
Animals that showed neurological complications or were immobile were also immediately
culled, regardless of other observed clinical signs.
Assessment of virulence in mice
For each of the eleven AT mutants and the wild-type 10276 parent strain, an initial evaluation
of virulence was performed by challenging groups of six BALB/c mice (6–8 weeks old) via the
intra-peritoneal route with 105 CFU. Mice were monitored for signs of disease over a 35 day
period and humanely culled when pre-defined end-points were reached by cervical dislocation
according to Schedule 1 of the Animal (Scientific Procedures) Act 1986.
The eight AT mutants which displayed attenuation for virulence relative to the wild-type
10276 strain were subsequently tested in six groups of five female BALB/c mice (6–8 weeks
old). Mice were separately challenged by the intra-peritoneal route at doses rising in ten-fold
increments from 102 to 107 CFU (five mice per dose per strain). Mice were monitored for signs
of disease over a 35 day period and humanely culled when pre-defined end-points were
reached by cervical dislocation according to Schedule 1 of the Animal (Scientific Procedures)
Act 1986. The median lethal dose was determined using the Reed and Muench calculation
based on cumulative death.
Analysis of net intracellular replication in J774.2 murine macrophage-like
cells
The intracellular survival and/or replication of B. pseudomallei strains in monolayers of the
macrophage-like J774.2 cell line was assessed as previously reported [21]. Briefly, J774.2 cell
monolayers were infected with B. pseudomallei at an MOI of 10 for 1 h then washed in phos-
phate-buffered saline (PBS) and incubated for a further 15 h in Dulbecco’s modified Eagle me-
dium (DMEM) + 10% (v/v) heat inactivated foetal calf serum (FCS) containing gentamicin
and spectinomycin (192 μg/ml and 384 μg/ml) to kill extracellular bacteria. Growth media was
supplemented with 25 μg/ml tetracycline and 10 mM IPTG as required. J774.2 cells were lysed
with 0.2% (v/v) Triton X-100 and viable bacteria were enumerated by incubation on LA agar
plates. Data for the eleven AT mutants (the output CFU of the mutant strain divided by the
input CFU) was normalised against the wild-type data and the normalised values from dupli-
cate samples in five independent experiments were expressed as the mean and standard error
of the mean; statistical significance was analysed using Student’s t test.
Serum resistance assays
NHS was collected from healthy adult volunteers (n = 2) with informed written consent in ac-
cordance with the requirements of the Human Tissue Act (2004) with the approval of the
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University of Leicester Local Ethical Review Committee which reviewed both the collection
and consent procedures. Serum resistance assays were performed as previously reported [6].
Briefly, B. pseudomallei strains were added at 106 CFU to 45% (v/v) NHS in PBS and bacterial
survival was enumerated after 3 h by plating onto LA. Serum was supplemented with 25 μg/ml
tetracycline and 10 mM IPTG during plasmid-mediated trans-complementation. Assays were
performed using duplicate samples over four independent experiments or quadruplicate sam-
ples over three independent experiments (depending on the number of samples per
experiment).
Polysaccharide staining
The bpaCmutant and its parent wild-type 10276 strain were assessed for the presence of poly-
saccharide capsule using immunofluorescence microscopy [30] and LPS using silver staining
[31] and immunoblotting [32]. For capsule, mid-logarithmic phase cultures of the B. pseudo-
mallei strains were air-dried onto microscope slides and fixed overnight with 4% (w/v) PFA
prior to staining for 1 h with the type I O-PS capsule monoclonal antibody 4V1H12 (1 μg/ml)
followed by goat anti-mouse IgG Alexa Fluor 488 (Molecular Probes, Invitrogen, Paisley, UK)
at a 1:250 dilution for 1 h. Stained bacteria were observed using immunofluorescence micros-
copy and a minimum of nine fields of view were observed. For LPS, overnight cultures of the
B. pseudomallei strains were pelleted by centrifugation and the bacterial cells lysed by boiling
for 10 minutes in 300 μl 1x SDS-PAGE sample buffer prior to Proteinase K (0.5 mg/ml) treat-
ment for 1 h at 60°C. Samples were loaded in duplicate onto 17% (v/v) polyacrylamide Tris-
buffered gels without SDS. Carbohydrates were visualised by silver staining of the oxidised gel
(0.35% (v/v) periodic acid treatment) using SilverQuest (Invitrogen, Paisley, UK) as per manu-
facturer’s instructions. Additionally, the gel was transferred onto Hybond ECL nitrocellulose
membranes (GE Healthcare, Little Chalfont, UK) by semi-dry blotting (Sigma-Aldrich) as per
manufacturer’s instructions. The membrane was blocked overnight in 0.5% (w/v) milk powder
followed by primary antibody detection with anti-B.mallei LPS monoclonal antibody (AbCam,
Cambridge, UK) and secondary antibody detection with anti-mouse IgG AP-linked antibody
(Cell signalling Technology, Hitchin, UK). Antibodies were used at a dilution of 1:2000 for 1 h.
RNA Isolation and analysis
RNA was isolated from B. pseudomallei strains using the TRIzol reagent (Invitrogen, Paisley,
Scotland) as per manufacturers’ instructions. Briefly, cells were harvested from mid-log cul-
tures at an OD650 of 1.0 and resuspended in 1 ml TRIzol. Proteinaceous impurities were re-
moved by duplicate chloroform extraction steps and RNA was precipitated with 0.6 volume
isopropanol, washed with 70% (v/v) Ethanol and resuspended in 100 μl H2O. To remove con-
taminating DNA, RNA (1 μg) was incubated with 6U DNase in 10x buffer (Fisher, Loughbor-
ough, UK) in a total volume of 100 μl for 60 minutes at 37°C. RNA was then purified using
RNeasy columns (Qiagen, Hilden, Germany) as per the manufacturer’s instructions. The
DNase treatment was repeated a second time prior to reverse transcription.
Reverse transcription of RNA (500 ng) to obtain cDNA was performed using 50 ng random
hexamers and RevertAid reverse transcriptase (Fermentas, Loughborough, UK) as per manu-
facturers’ instructions. Negative control reactions were performed concurrently with the re-
verse transcriptase omitted to confirm complete removal of gDNA from each sample. cDNA
was then used in PCR amplifications as described for recombinant DNA techniques above. Re-
sulting PCR products were visualised on 0.8% (w/v) agarose gel using a Syngene G:Box with its
proprietary GeneSnap v7.12.02 software (Syngene, Cambridge, UK). Duplicate biological sam-
ples were tested and densitometry was performed against the gDNA (15 ng) positive control.
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Protein expression and purification
Recombinant N-terminal GST fusion proteins were expressed in E. coli BL21 (DE3) cells. Bac-
terial strains harbouring pGEX4T1 constructs were grown in 200 ml LB and protein expression
induced with 1 mM IPTG at an OD650 of 0.6 to 0.8 at 37°C for 6 h. Cells were harvested by cen-
trifugation and lysed in lysozyme (10 mg/ml) prior to sonication. Insoluble inclusion bodies
were purified by sequential wash and centrifugation steps in 2 M urea followed by overnight in-
cubation at -20°C. The resulting supernatant was subjected to dialysis against PBS to remove
urea. Soluble recombinant fusion proteins were quantified by the Coomassie (Bradford) Pro-
tein Assay kit (Thermo Scientific, Loughborough, UK) using a BSA standard curve as per man-
ufacturer’s instructions and proteins were adjusted to a final concentration of 1 mg/ml.
Immune recognition of recombinant proteins
The recombinant N-terminal GST fusion proteins were used as antigens to test the immune re-
sponse against ATs. The four antigens (0.3 μg/ml) were used to restimulate lymphocytes in
whole blood from seropositive donors (WB) (n = 2), alongside phytohaemagglutinin (PHA)
and paraformaldehyde (PFA)-fixed B. pseudomallei strain K96243 positive controls. Whole
blood was collected from healthy adult volunteers in the (endemic) Khon Kaen area of North-
eastern Thailand with informed written consent; the study, including the consent form, was re-
viewed and approved by the Khon Kaen University Ethics Committee for Human Research.
Seropositive donors were then identified by using the indirect haemagglutination assay; a titer
of 40 was considered seropositive. The IFN-γ response of WB was measured by ELISA as
previously described [33]. IFN-γ production indicates lymphocyte activation (memory) in re-
sponse to the specific antigens tested.
The four antigens were also tested for recognition by seropositive sera from melioidosis
endemic area using an indirect sandwich ELISA. A 96-well plate was coated with 3 μg/ml
crude B. pseudomallei antigen extracted from clinical isolates as described previously [34] or
10 μg/ml of each recombinant protein; uncoated wells served as a background absorbance con-
trol. The plate was probed with a 1:300 dilution of plasma from healthy seropositive volunteers
(n = 15) prior to detection with a 1:10,000 dilution of biotinylated anti-human IgG and Strepta-
vidin-horse radish peroxidase. The ELISA plate was read at OD450; results were represented by
absorbance index (test absorbance minus the background divided by the background). Dupli-
cate experiments were performed; statistical significance was calculated using one way
ANOVA with Tukey’s post test.
Results and Discussion
ATs play a role in the virulence of B. pseudomallei
As part of a systematic study on the ATs of B. pseudomallei, we constructed and validated in-
sertion mutants in all eleven predicted ATs of the virulent strain 10276 as detailed in Materials
and Methods. Predictions were based on published searches (reviewed in [35]). All eleven mu-
tants were tested alongside their isogenic parent 10276 strain and found to display wild-type
levels of in vitro growth in LB media (data not shown). To assess the role of ATs in the viru-
lence of B. pseudomallei, these mutants and the wild-type 10276 parent strain were tested for
virulence in a BALB/c mouse model of melioidosis. An initial single dose virulence screen dem-
onstrated attenuation for virulence for eight AT mutant compared to the wild-type strain (data
not shown). Therefore, six groups of five mice were separately challenged by the intra-peritone-
al route with rising doses of each of these eight AT mutants. The median lethal dose (MLD) of
the eight AT mutants or wild-type 10276 was determined by the using the Reed and Muench
Autotransporters of B. pseudomallei
PLOSONE | DOI:10.1371/journal.pone.0121271 April 1, 2015 9 / 21
calculation based on cumulative lethal dose. Compared to the parent 10276 strain (MLD 1.6 x
104 CFU), eight of the AT mutant strains exhibited an increase in median lethal dose of be-
tween 1 to 2-log10; bpaA (1.52 x 10
6 CFU), bpaC (1.02 x 106 CFU), bpaE (6.34 x 105 CFU),
boaB (6.13 x 105 CFU), bcaA (5.78 x 105 CFU), bbfA (2.09 x 105 CFU), boaA (1.6 x 105 CFU)
and bimA (1.6 x 105 CFU) (Table 3). These data reveal that the majority of ATs, with the excep-
tion of BatA, BpaB and BpaD, play a role in the virulence of B. pseudomallei.
Our virulence data diverges from previously published data from the two studies by Campos
et al., 2013 [15,17], where attenuation was only detected for the bpaCmutant within the liver
of the intra-nasal mouse model. However, consistent with these observations, the bpaCmutant
demonstrated the second highest median lethal dose in our experiments. The studies of Cam-
pos et al., 2013 [15,17] involved infection via the intra-nasal route, which resulted in an early
acute disease with bacterial burdens of 105 to 108 CFUs in the liver and spleen by 48 h. As ac-
knowledged by the authors, this highly acute model is unlikely to detect moderate attenuation
levels observed in our animal model over a longer time course, where intra-peritoneal dosing
produces morbidity several weeks after challenge rather than several days as with intra-nasal
administration (reviewed in [36]).
The intra-tracheal aerosol infection data for the bpaCmutant obtained by Lafontaine et al.,
2014 [18], also represents an early acute disease although this route of infection has been
shown to target the lungs [37] rather than the nasal cavity [38] tropism noted for intra-nasal
infection. The difference in target site for primary infection may explain the why the bpaCmu-
tant displayed a median lethal dose similar to its parent strain via the intra-tracheal aerosol
route [18]. It is important to note that the independent bpaCmutants were constructed using
different methods (deletion [18] versus insertion [15] mutants). Insertion mutants can result in
the expression of truncated proteins, which can potentially cause attenuation. To minimize any
possible negative dominant effects, our insertion mutants were designed so that should protein
expression occur, only a significantly truncated protein (representing approximately 24% of
the full-length AT) could be translated (Table 2). It is also important to remember, that any
Table 3. Virulence of B. pseudomallei autotransporter mutants in a murinemodel of melioidosis.
K96243 gene Nomenclature Function Attenuation (MLD compared to wild-type)
Wild-type 10276
- - - 1.6 x 104 CFU
Classical autotransporters
BPSL2237 BatA N/D
BPSS0962 BcaA ✓ (5.78 x 105 CFU; 36-fold)
Trimeric autotransporter adhesins
BPSL1631 BpaC ✓ (1.02 x 106 CFU; 64-fold)
BPSL1705 BoaB ✓ (6.13 x 105 CFU; 38-fold)
BPSL2063 BpaB N/D
BPSS0088 BpaD N/D
BPSS0796 BoaA ✓ (1.6 x 105 CFU; 10-fold)
BPSS0908 BpaE ✓ (6.34 x 105 CFU; 40-fold)
BPSS1434 BpaA ✓ (1.52 x 106 CFU; 95-fold)
BPSS1439 BbfA Bioﬁlm formation [21] ✓ (2.09 x 105 CFU; 13-fold)
BPSS1492 BimA Actin polymerisation [22] ✓ (1.6 x 105 CFU; 10-fold)
N/D = not done
doi:10.1371/journal.pone.0121271.t003
Autotransporters of B. pseudomallei
PLOSONE | DOI:10.1371/journal.pone.0121271 April 1, 2015 10 / 21
potential truncated ATs would lack their C-terminal translocator domain; thus, would be re-
tained in the periplasmic space.
An additional difference between these previous studies is the choice of strain background;
while both groups used strain 1026b, each study used a 1026b mutant lacking different antibi-
otic resistance genes. In the study by Campos et al., 2013, Bp340 [39], a 1026b background
strain with a deletion in the genes encoding the antibiotic efflux pump bpeAB-oprB was used
while in the study of Lafontaine et al., 2014, DD503 [40], a 1026b background strain with a de-
letion in the genes encoding a second antibiotic efflux pump amrR-oprA was used. The DD503
strain has been previously reported to display an increased median lethal dose of 2.5 log10 rela-
tive to its 1026b wild-type parent in the whole body aerosol model in BALB/c mice [41]. Con-
versely, the median lethal dose for 1026b via the intra-tracheal aerosol route previously
published by Lafontaine et al., 2014 [37] was 0.5 log10 higher than the median lethal doses of
DD503 and the bpaCmutant. Contradictory pleiotropic phenotypes for bpeAB-oprBmutants
in the 1026b and KHW strains have also been reported including defects in biofilm formation,
quorum sensing and infection of epithelial and macrophage cell lines [39,42]. Therefore, in ad-
dition to the suggestion of Lafontaine et al., 2014 [18] that testing of various infection models is
required for a full understanding of the role of BpaC in pathogenesis, further investigation of
the strain-dependent effects should be assessed.
Five of the genes encoding ATs occur within operons as defined by the comprehensive tran-
scriptome study of Ooi et al., 2013 [43] (bcaA, bpaB, bpaE, bbfA and bimA). Of these, four ex-
hibit attenuation of virulence. The bbfAmutant has been previously identified to play a role in
biofilm formation and virulence and both of these mutant phenotypes were rescued by trans-
complementation implying a lack of polarity [21]. Additionally, the defect in actin-based motil-
ity of a bimAmutant can be fully rescued by plasmid-mediated trans-complementation within
J774.2 macrophage-like cells and the original annotation of the locus shows bimA to be the last
predicted gene in an operon [22]. The bcaA and bpaE genes are the first in predicted two-gene
operons and we cannot preclude the possibility that the downstream genes (respectively pre-
dicted to encode a hypothetical protein and an OmpA family protein) may contribute to the
observed phenotypes of the insertion mutants in mice.
Four ATs have a significant effect on net intracellular replication of B.
pseudomallei in J774.2 macrophage-like cells
Previous studies have demonstrated that most of the B. pseudomallei ATs play a role in adhe-
sion, invasion and/or plaque formation in epithelial cell lines [15,17–19]. However, only bimA,
bbfA and bpaCmutants of B. pseudomallei have been tested for intracellular survival in phago-
cytic cells [21,23] with only the bimAmutant found to display reduced survival and/or replica-
tion. Therefore, we assessed the role of ATs in the survival and/or replication of B.
pseudomallei within the macrophage-like J774.2 cell line as detailed in Materials and Methods.
Four AT mutant strains demonstrated significantly reduced net intracellular replication rela-
tive to the wild-type: bimA (0.38± 0.12, p = 0.0009), bpaE (0.67± 0.08, p = 0.0037), bpaC (0.51±
0.13, p = 0.0061) and boaB (0.52± 0.21, p = 0.0500) (Fig. 1). Data were consistent with our earli-
er data for the bbfAmutant [21] and unpublished observations for the bimAmutant recorded
by Stevens et al., 2005 [22]. However, our results were not in accordance with the published
data for a bpaCmutant tested by Campos et al., which did not demonstrate a defect in net in-
tracellular survival of J774A.1 macrophage-like cells in their study [18]. Differences in the mac-
rophage cell line, assay time (8 h [18] versus our 16 h) or bacterial strain variation may explain
this disparity.
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The four AT mutant strains which demonstrated reduced net intracellular survival were not
those which displayed the highest levels of attenuation of virulence in mice (Table 3). The im-
portance of the intracellular phase of infection has not been elucidated and such results high-
light the need for in-depth studies into this nascent area. The four mutants attenuated for net
intracellular replication, bimA, bpaE, bpaC and boaB, are all TAAs, although these are overrep-
resented in the B. pseudomallei genome [35]. Though bimA has been demonstrated to play a
role in plaque formation [22], we present the first compelling evidence of an important role for
this factor in B. pseudomallei virulence and net intracellular growth, in contrast with the ab-
sence of attenuation of a B.mallei bimAmutant in a Syrian hamster model of acute glanders
[44]. Mutants lacking the three other TAAs required for net intracellular replication (bpaE,
bpaC and boaB) were examined by fluorescence microscopy and found to form normal actin
tails during infection of macrophage-like cells (data not shown).
A B. pseudomallei bpaCmutant is sensitive to complement-mediated
killing by normal human serum via the classical and/or lectin pathway of
the complement system
The reported functions of ATs include a role in serum resistance in a variety of organisms,
including the related respiratory pathogens Burkholderia cenocepacia [45] and Bordetella per-
tussis [46]. To investigate the role of ATs in serum resistance, the eleven B. pseudomallei AT
mutants and the wild-type 10276 parent strain were tested for survival in 45% (v/v) NHS after
3 h incubation (data not shown and Fig. 2). Only one B. pseudomallei strain, the bpaCmutant,
demonstrated significantly reduced survival in serum. These data are not in accordance with
the previously published bpaCmutant [18] which did not demonstrate a defect in bactericidal
activity of 50% (v/v) NHS. However, in addition to using a different bacterial strain, the authors
of this report enumerated bacteria at 30 minutes post-exposure [18] rather than 180 minutes
Fig 1. Net intracellular replication of the B. pseudomallei ATmutants in J774.2 macrophage-like cells.
Viable intracellular bacteria were enumerated (output divided by input CFU) for the duplicate experimental
samples of each of the AT mutants and the data was normalised against the wild-type parent strain. Data
from five experiments was expressed as the mean and standard error of the mean; statistical significance
was analysed using Student’s t test.
doi:10.1371/journal.pone.0121271.g001
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post-exposure as in the present study. Congruently, we found that the serum sensitivity pheno-
type of the bpaCmutant was not statistically significant at 30 minutes (data not shown).
To further evaluate the ability of B. pseudomallei to resist the complement-mediated killing
of NHS, the wild-type and bpaCmutant strains were assessed for survival in NHS with and
without the addition of 10 mM EDTA (inactivation of complement activity) or 10 mM EGTA,
5 mMMgCl2 (inactivation of the classical and lectin arms of the complement pathway). The
bpaCmutant exhibited a 1.1-log10 reduction in survival compared to the wild-type in 45%
(v/v) NHS after 3 h incubation relative to the parent strain (1.08 x 103 CFU versus the 1.22 x
104 CFU input, p = 0.0003) (Fig. 2). This serum sensitivity was abolished by disruption of all
complement as well as by specific inactivation of the classical and/or lectin pathway (Fig. 2A).
Both polysaccharide capsule and the LPS are important for serum resistance; therefore, it is
important to ensure that disruption of the bpaC gene did not result in any disruption to these
polysaccharides. The bpaCmutant and its parent wild-type 10276 strain were assessed for the
presence of capsular material using immunofluorescence microscopy and for LPS using silver
staining and immunoblotting as detailed in Materials and Methods. Thus, we can confirm that
both polysaccharide capsule and LPS, important serum resistance factors, are expressed in the
bpaCmutant (S1 Fig.).
The mechanism of action of ATs mediating serum resistance varies greatly. The prototypical
TAA, YadA from Yersinia spp., binds serum complement regulatory factors from both the al-
ternative and classical/ lectin pathway; factor H and C4 binding protein respectively [47,48].
The serum resistance TAAs ofMoraxella catarhalis, UspA1 and UspA2, also bind C4 binding
protein [49], in addition to factor C3d [50]. Bordetella pertussis has multiple ATs involved in
serum resistance, including BrkA, BapC and Vag8. BrkA and Vag8 both inhibit the classical
and/or lectin pathway. BrkA prevents C4 deposition via an uncharacterised mechanism [51]
while Vag8 binds to the C1 inhibitor in a BrkA-independent manner [46]. BapC has an
Fig 2. The bpaCmutant is sensitive to complement-mediated killing. The bpaCmutant demonstrates a
1.1-log10 reduced survival in 45% (v/v) NHS after 3 h incubation relative to the parent strain (1.08 x 10
3 CFU
versus the 1.22 x 104 CFU input, p = 0.0003). This sensitivity could be abrogated by the addition of 10 mM
EDTA or 10 mM EGTA, 5 mMMgCl2. Graphs showmean results with error bars displaying standard error of
the mean; statistical significance was calculated using Student’s t test.
doi:10.1371/journal.pone.0121271.g002
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additive effect on BrkA serum resistance but its mechanism of action is unknown [52]. The
Haemophilus ducreyi TAA DsrA mediates serum resistance by binding IgM [53]. Escherichia
coli also encodes a family of five TAAs (EibA, C, D, E and F) which bind the Fc fragment of
IgG and/or IgA [54]. In B. pseudomallei, the observed serum resistance phenotype of the bpaC
mutant could be due to BpaC-mediated interaction(s) with classical and/or lectin pathway reg-
ulators, for example C1 inhibitor or C4 binding protein, or by the binding of non-specific im-
munoglobulins [7]. Further studies are required in order to elucidate the target complement
factor, as well as the mechanism and required domains of this BpaC-mediated
serum resistance.
Complementation of the serum sensitivity and intracellular survival
phenotypes of the bpaCmutant
To confirm that the observed human serum sensitivity was due to the disruption of bpaC, the
bpaCmutant was complemented in trans with the inducible pME6032 vector containing a full-
length copy of the bpaC gene. Additionally, B. pseudomallei wild-type and a bpaC strain har-
bouring empty pME6032 (pME) vector were used as controls to account for any potential ef-
fects of the plasmid per se on serum resistance. Serum assays were repeated as described
previously and a significant reduction in serum resistance of the bpaC (pME) strain was ob-
served relative to the wild-type (pME) strain. However, serum resistance by the complemented
bpaC (pME-bpaC) strain was restored to wild-type levels in the presence of inducer (Fig. 3A).
Therefore, it can be concluded that BpaC is a novel serum resistance factor that mediates resis-
tance to the classical and/or lectin arms of the complement pathway.
Following the successful complementation of the bpaCmutant for in vitro serum resistance
assays, we repeated the macrophage assays as described previously. The B. pseudomallei wild-
type and bpaC strains harbouring empty pME6032 (pME) vector resulted in a loss of fitness for
both bacterial strains under the intracellular experimental conditions. Therefore, these controls
were replaced with a B. pseudomallei wild-type and a bpaC strain harbouring the previously re-
ported pME6032 plasmid containing a full-length copy of the bbfA gene (pME-bbfA) [21]. A
significant reduction in net intracellular survival of the bpaC (pME-bbfA) mutant strain was
observed (0.18± 0.06, p<0.001 normalised against the wild-type strain harbouring pME-bbfA)
(Fig. 3B), supporting the effect of bpaCmutation seen in Fig. 1. The net intracellular replication
of the complemented bpaC (pME-bpaC) was largely restored in the presence of inducer (0.71±
0.33, p = 0.411 relative to the wild-type) (Fig. 3B). Therefore, it can be concluded that BpaC has
a role in net intracellular survival of B. pseudomallei 10276 in phagocytic cells.
Finally, an attempt at in trans complementation of the bpaCmutant virulence phenotype
was performed using the competitive in vivo growth assay method successfully used to confirm
a direct role for BbfA in virulence [21]. Unfortunately, the pME6032 plasmid harbouring a
full-length copy of bpaC complementation vector did not rescue the bpaCmutant phenotype
despite negligible loss of plasmid over the 24 h experimental period (data not shown). As bpaC
is not predicted to be encoded in an operon, polar effects of the insertion are unlikely. Howev-
er, it is also possible that the cloned 117 bp upstream region does not contain the full promoter
region(s) for expression. Given this assumption, bpaC gene expression would need to be driven
by exogenous IPTG. Induction with IPTG occurred via in vitro addition during the serum as-
says and macrophage uptake from supplemented cell culture media for the macrophage assays
but was not present during in vivo animal studies. Experimental results for the in vitro serum
assay and intracellular macrophage assay concur with this hypothesis as complementation lev-
els were significantly higher in the serum assays for which IPTG was more readily accessible
(Fig. 3). To test this hypothesis, we incubated the bpaCmutant harbouring the
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complementation vector in LB medium with and without the addition of 10 mM IPTG and iso-
lated total bacterial RNA. Each of the RNA samples was then transcribed to obtain cDNA
using reverse transcriptase and PCR amplification was performed using primers specific for
the bpaC gene region downstream of the single cross-over insertion as detailed in the Materials
and Methods. Densitometry analysis of the resulting PCR products indicated a low level of the
bpaC transcript was present in the non-induced sample (0.75 of the value obtained for the
15 ng gDNA control); whereas, addition of IPTG resulted in an approximately 4-fold increase
of the bpaC transcript (2.75 relative to the gDNA control). Thus, expression of the bpaC gene
from the complementation vector occurs effectively under IPTG induction.
It has previously been reported that an independent bpaCmutant demonstrated attenuation
for virulence in the BALB/c intra-nasal mouse model [15], suggesting that bpaC plays a role in
B.pseudomallei pathogenesis. Our data presented here further support this notion and indicate
that this AT may do so by contributing to serum resistance and intracellular survival of
the pathogen.
BpaE and BcaA are capable of inducing humoral and cell-mediated
immune responses
Seven TAAs have been shown to be recognised by melioidosis patient sera antibodies in two
separate screens, indicative of in vivo expression and immunogenicity of these ATs ([16,20];
Table 3). Thus, we expressed recombinant N-terminal GST fusion proteins of the passenger
domain of four predicted ATs to be used as antigens to test the immune response against these
ATs. All recombinant proteins were examined by Western blot using anti-GST antibodies and
Fig 3. Complementation of the bpaCmutant serum sensitivity and intracellular survival phenotypes. a. Complementation of the bpaCmutant with a
full-length copy of the bpaC gene expressed in trans by the inducible pME6032 vector (pME-bpaC) abrogated the serum sensitive phenotype seen for the
bpaCmutant harbouring empty pME6032 vector (pME). Graphs showmean results with error bars displaying standard error of the mean; statistical
significance was calculated using Student’s t test. b. Complementation of the bpaCmutant with a full-length copy of the bpaC gene expressed in trans by the
inducible pME6032 vector (pME-bpaC) partially complemented the defect in net intracellular replication seen for the bpaCmutant harbouring pME6032
vector with a full-length copy of the bbfA gene (pME-bbfA). Graphs show normalised mean results with error bars displaying standard error of the mean;
statistical significance was calculated using Student’s t test.
doi:10.1371/journal.pone.0121271.g003
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confirmed to be of expected size; no degradation products were detected (data not shown).
These four ATs represented each of the phenotypic groups identified in the three pathogene-
sis-associated assays detailed above (Fig. 4): those attenuated for virulence in the BALB/c
intra-peritoneal mouse melioidosis model (BcaA), those attenuated for virulence and net intra-
cellular replication in J774.2 macrophage-like cells (BpaE), the BpaC mutant with defects in
virulence, net intracellular replication and serum resistance in 45% (v/v) normal human serum
and those displaying wild-type phenotypes (BatA). This includes both classical ATs (BcaA and
BatA) and two of the predicted TAAs (BpaE and BpaC). Only one of these antigens, BpaE, has
been previously shown to be recognized by host immunity, although BpaC-specific antibodies
have been detected in response to infection of BALB/c mice with B. pseudomallei [18].
Soluble recombinant N-terminal GST fusion proteins were used as antigens to test the im-
mune response against ATs. The four antigens (1 μg/ml) were used to stimulate whole blood
from human seropositive donors, alongside mitogen (PHA) and fixed B. pseudomallei K96243
positive controls as detailed in Materials and Methods. The IFN-γ response of whole blood
from seropositive donors was measured by ELISA and is indicative of lymphocyte reactivation
to the antigens tested. BpaE and BcaA elicited a strong average IFN-γ response across the do-
nors (225.4 pg/ml ± 45.7 pg/ml and 214 pg/ml ± 56.7 pg/ml respectively; p value<0.001) rela-
tive to the medium-only control average (4.99 pg/ml ± 1.7 pg/ml) while BpaC and BatA did
not induce a statistically significant lymphocyte recall response across the donors (Fig. 5A).
The four antigens were also tested for recognition by seropositive sera from an area where
melioidosis is endemic using an indirect sandwich ELISA as detailed in Materials and Methods.
Fig 4. Systematic assessment of ATs for three pathogenesis-associated phenotypes. A Venn diagram
of the phenotypic results of the complete repertoire of ATs for virulence in the BALB/c intra-peritoneal mouse
melioidosis model, net intracellular replication in J774.2 macrophage-like cells and survival in 45% (v/v)
normal human serum.
doi:10.1371/journal.pone.0121271.g004
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BpaE and BcaA (absorbance index of 7.96 ± 0.82 and 4.86 ± 0.55 respectively; p value<0.001)
were both recognised by seropositive human sera from the endemic area while values for nei-
ther BpaC nor BatA were significantly different from the negative control (Fig. 5B).
The immunogenicity data demonstrates that two of the ATs tested (BpaE and BcaA) are ca-
pable of eliciting humoral and cell-mediated responses in human melioidosis patients. Only
one of these two ATs, BpaE, has been previously identified as immunogenic [16,20]; however,
our study used a different experimental method to both previous studies so it is unsurprising
that different antigens were identified. Neither BpaC nor BatA elicited a consistent lymphocyte
recall response nor were these antigens recognised by seropositive patient serum, at least at the
limit of detection of the assays used. BpaC has been previously demonstrated to be expressed in
vivo by B. pseudomallei in BALB/c mice during acute infection [18], but if BpaC-specific anti-
bodies were produced by the human melioidosis patients, they were not detected by our assays.
This may relate to a degree of variation noted in domain repeats of BpaC across B. pseudomallei
strains [18], or reflect differences in the immune response between hosts (murine versus
human). In the case of the BatA, when these data are taken together with the fact that the bpaB
Fig 5. Immune recognition of recombinant proteins. a) Recombinant N-terminal GST fusion proteins of the passenger domain of four ATs were used as
antigens (1 μg/ml) to stimulate whole blood (WB) from human seropositive donors, alongside PHA and fixed B. pseudomallei strain K96243 positive controls.
The IFN-γ response of WB was measured by ELISA. BpaE and BcaA (225.4 pg/ml ± 45.7 pg/ml and 214 pg/ml ± 56.7 pg/ml respectively; p value<0.001)
relative to the medium-only control average (4.99 pg/ml ± 1.7 pg/ml) elicited a strong IFN-γ response fromWB from seropositive donors (n = 2; black and grey
bars represent the two individual donors) while BpaC and BatA did not induce a significant lymphocyte recall response. b) The four antigens were also tested
for recognition by human seropositive sera from a melioidosis endemic area using an indirect sandwich ELISA. BpaE and BcaA (absorbance index of
7.96 ± 0.82 and 4.86 ± 0.55 respectively; p value<0.001) were both recognised by seropositive human sera from the endemic area while values for neither
BpaC nor BatA were significantly different from the negative control.
doi:10.1371/journal.pone.0121271.g005
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mutant displays wild-type virulence and net intracellular replication, it suggests that this AT
may not be highly expressed in vivo.
To conclude, we have systematically mutated eleven predicted ATs of B. pseudomallei strain
10276 and assigned roles to eight of these in the pathogenesis of melioidosis in a murine intra-
peritoneal challenge model, of which four also contributed significantly to net intracellular rep-
lication in macrophage-like cells in vitro. We also identified a novel serum resistance factor,
BpaC, which mediates resistance to killing by the classical and/or lectin arms of the comple-
ment pathway. Further studies are required in order to elucidate the mechanism of BpaC-me-
diated serum resistance and to determine the value of virulence-associated and immunogenic
ATs in the development of strategies to control melioidosis.
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